American Association for Cancer Research (AACR), 2023.
سنة النشر:
2023
الوصف:
Supplementary Information (5 sections): Study design; Review of prior studies to validate the technical robustness of REMI; Selection of cell-surface biomarkers for REMI of breast tumors; Spectral demultiplexing to quantify SERS NPs; Cell culture and flow cytometry for the validation of conjugated NPs Supplementary Figures (10 figures): Supplementary Figure S1. Linearity and limit-of-detection of spectral measurements. Supplementary Figure S2. REMI of normal tissue (EGFR-negative) and tumor xenograſts (SkBr3, U251, and A431) that express various levels of EGFR. Supplementary Figure S3. Structure and spectra of SERS NPs. Supplementary Figure S4. Flow-cytometry based validation of the binding of targeted NPs to cell-surface receptors on cultured cells. Supplementary Figure S5. REMI enables the detection of double-positive breast tumor (ER+ and HER2+). Supplementary Figure S6. REMI enables the detection of EGFR in a triple-negative breast tumor. Supplementary Figure S7. REMI of fibroadenoma (benign lesion). Supplementary Figure S8. An illustration of a key difference between staining histological tissue sections and fresh tissue surfaces. Supplementary Figure S9. Comparison of traditional single-targeted-agent imaging vs. ratiometric imaging, in which an untargeted agent is used to normalize for the nonspecific accumulation that occurs for all agents. Supplementary Figure S10. Comparison of ROC curves for identification of biomarker expression using (A) a ratiometric imaging strategy (same as Fig. 5B) and (B) a traditional single-targeted-agent strategy. Supplementary Table S1. Benign lesions. Supplementary Table S2. Molecular profile of patients.